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The discouraging results from the recent human HIV trial performed by Merck and collaborators, named "STEP," raises serious questions about current vaccine approaches using replication-defective viral vectors \[[@CR1_18]\]. This study was an international phase II "test of concept" trial in uninfected volunteers at high risk for acquiring HIV infection which showed that vaccination using a recombinant adenovirus serotype 5 vector was ineffective at preventing virus infection and even increased the rate of transmission in individuals exhibiting prior immunity to the viral vector. While this vaccine was safe and immunogenic in both humans and nonhuman primates, eliciting long-lasting and multifunctional CD8^+^ T cell responses that were partially protective in rhesus macaques, the discovery that the vaccine could possibly heighten HIV infection was both unexpected and alarming, resulting in the immediate discontinuation of vaccinations as recommended by the independent Data Safety Monitoring Board for STEP. Since preexisting immunity against a vaccine vector may compromise its efficacy in humans, future vaccine approaches should aim to utilize vectors that exhibit minimal or no reactivity in immunocompetent vaccines.

DNA vaccination consists of the administration of genetic material encoding a desired antigen that when expressed in the vaccine, is capable of eliciting an immune response. Compared with other approaches, the advantages of DNA vaccination are many \[[@CR2_18]\]; no infectious agents are involved and vaccines are unable to revert into virulent form like live vaccines. They can prime both cytotoxic \[[@CR3_18]\] and humoral responses \[[@CR4_18]\], and DNA vectors are easily manipulated, can be tested rapidly, produced at high yield in bacteria, and are readily isolated. They are also more temperature-stable than conventional vaccines, easily stored and transported, and do not require a cold chain. Furthermore, DNA vaccines could potentially induce immunity in newborns in situations that usually neutralize conventional vaccines via the presence of high levels of maternal antibodies \[[@CR5_18]\]. The introduction of exogenous DNA into cells or tissue can be achieved using DNA conjugates \[[@CR6_18]--[@CR10_18]\], virus-derived vectors \[[@CR11_18]\], or naked plasmid DNA (pDNA) \[[@CR12_18]\]. Naked pDNA shows variable and low transfection efficacy when administered by conventional means, such as needle injection or topical application. However, several strategies aimed to improve pDNA vaccine immunogenicity have been developed, including codon optimization \[[@CR13_18]\], mRNA optimization \[[@CR14_18]\], addition of leader sequences \[[@CR15_18]\], and construction of consensus immunogens \[[@CR16_18]\]. While these strategies help to boost the overall immunogenicity of a DNA vaccine, they may not be applicable to all antigens. Recently, electroporation, or electropermeabilization, has gained great interest in multiple research areas including gene therapy and vaccinology \[[@CR17_18]\]. Although the precise mechanism of action has not yet been well defined, it is hypothesized that cell membranes in host tissue receiving electroporation, normally impermeable to charged molecules, form pores or functionally equivalent structural changes upon application of an external electric field which facilitate the influx of macromolecules. Thus, higher transfection efficacy of naked pDNA as a result of electroporation is thought to be the major contributor to the increased immunogenicity of electroporation-mediated DNA vaccination. In addition, it has been shown that electroporation increases vaccine potency by activating antigen-presenting cells (APCs) via danger signals and local inflammation \[[@CR18_18]\] and by recruiting immune cells to the site of DNA administration \[[@CR19_18], [@CR20_18]\]. Furthermore, direct transfection of APCs could also be facilitated by electroporation. Currently, intensive investigation is focused upon utilizing electroporation of muscle and skin as an effective method for DNA vaccine delivery to small and large animals, and in humans. The safety and feasibility of electroporation in humans has recently been demonstrated, but not finally proven \[[@CR21_18]\]. Thus, the paramount question for DNA vaccines at this time is whether a sufficient level of efficacy can be reached with the present methodology, or if further improvements or breakthroughs in vaccine design and/or electroporation delivery will be necessary.

In Vivo Transgene Expression After Gene Electrotransfer {#Sec2_18}
=======================================================

In 1990, the first transgene expression detected in ­skeletal muscle after injection of naked mRNA or pDNA raised the possibility of using this method for certain gene therapies and DNA vaccinations \[[@CR22_18]\]. Subsequently, transgene expression was also obtained in the same way in a wide variety of other tissues, but transgene expression was generally too low and variable to be useful for the envisioned purposes \[[@CR12_18]\]. Attempts to sufficiently enhance pDNA uptake, and thus transgene expression, with cationic lipids or the gene gun have also proven unsuccessful to date. The first publications on a substantial increase in transgene expression (about 100-fold) when electroporation was applied in vivo after pDNA injection appeared as late as 1996 \[[@CR23_18]\], although electroporation had been used for in vitro cell transfections since 1982 \[[@CR24_18]\]. In addition, as pointed out by Bettan et al. \[[@CR25_18]\], when using gene electrotransfer, a higher interindividual reproducibility in gene transduction can be observed.

Skeletal muscle (Fig. [18.1](#Fig1_18){ref-type="fig"}) has been the most frequently targeted tissue in both gene therapy and DNA vaccine studies, either with or without electroporation. Some reasons why muscle cells (also known as myocytes) and muscle tissues continue to be attractive targets for transgene expression include: muscle tissue is easily accessible, plentiful, and well vascularized; the latter facilitates circulation of the antigens produced by the transfected muscle cells. More discussion of gene electrotransfer to muscle can be found in 10.1007/978-1-4419-8363-3_16.Fig. 18.1Cellular targets of electroporation-mediated DNA vaccination. Current electroporation approaches following i.d. and i.m. DNA vaccination target skin cells (keratinocytes), muscle cells, and APCs (including Langerhans cells) by direct transfection (DT). Application of electroporation at a local immunization site induces the formation of transient complexes between the DNA and the lipids in the pore edges of the hydrophilic pore zones \[[@CR62_18]\] which facilitate the translocation of pDNA into the cell cytoplasm. Once in the cytosol, pDNA may gain access to the nucleus where transgene expression may occur

Electroporation and Plasmid DNA Vaccine Immunogenicity {#Sec3_18}
======================================================

In vivo electroporation has been used to deliver DNA vaccine encoding antigens from numerous infectious agents, summarized in Table [18.1](#Tab1_18){ref-type="table"}. Enhanced immune responses to electroporation-mediated DNA vaccination have been observed both in small and large animals such as mice \[[@CR26_18]\], pigs \[[@CR27_18]\], and monkeys \[[@CR28_18]\]. Widera et al. \[[@CR26_18]\] demonstrated in mice that upon electroporative treatment, the delivery of a weakly immunogenic hepatitis B virus (HBV) surface antigen (Hbs Ag) DNA vaccine resulted in an increased humoral immune response, characterized by rapid onset and higher titers of anti-Hbs Ag antibodies. In addition, the authors observed in the same study that the potency of an HIV *gag* pDNA vaccine was increased as shown by the lower dosage of DNA required to induce higher antigen-specific antibody levels and increased CD8^+^ T cell responses. Similarly, in a study carried out with a bovine herpes virus-1 truncated glycoprotein D DNA vaccine, Tsang et al. \[[@CR29_18]\] showed that the onset of the primary humoral response was earlier in the group treated with DNA followed by electroporation, and that this group produced higher antibody levels than those in the group receiving i.m. DNA immunization or a recombinant protein vaccine only; similar results were obtained earlier with an otherwise inert microparticulate adjuvant \[[@CR30_18]\]. Interestingly, the efficiency of transfection by electroporation was not increased by doubling the dose of DNA administered; however, the duration of the antigen-specific antibody response was increased at a higher rate in comparison to the immunization with the same dose of plasmid without electroporation. Moreover, electroporation increased the degree of consistency among the individuals in the DNA-plus-electroporation group as seen in the 5 weeks of follow-up. Finally, a high correlation between the duration of the primary immune response and the magnitude of the secondary antibody response was observed, implying that electroporation could represent an effective approach to elicit a longer memory antibody response.Table 18.1Antigens encoded by DNA vaccines used in combination with electroporationInfectious agentEncoded antigen(s)ModelDelivery routeReferencesHIVGagRhesus macaquesi.m.\[[@CR63_18]\]Gag and Env  +  IL-12Rhesus macaques\[[@CR36_18]\]EnvMice\[[@CR20_18]\]Gag and Env  +  IL-12Rhesus macaquesSkin\[[@CR36_18]\]Env  +  gp120 proteinMacaques and rabbitsi.m.\[[@CR64_18]\]Gag and EnvRhesus macaques\[[@CR65_18]\]Gag and EnvMicei.m.\[[@CR26_18]\]gp140Env, GagPol, and TatRevNef plasmidsRhesus macaques\[[@CR66_18]\]H5N1 virusHARabbits and micei.m.\[[@CR67_18]\]H1N1 virusNA; HAMicei.m.\[[@CR68_18], [@CR69_18]\]Avian influenza H9N2 virusHA and NAMicei.m.\[[@CR70_18]\]HBVpreS2-S  +  -2 and IFN-γRhesus macaquesi.m.\[[@CR71_18]\]preS(2)-S\[[@CR72_18]\]Hbs AgMice\[[@CR73_18]\]Hbs AgSheep\[[@CR74_18]\]Hbs AgRabbitsSkin\[ [@CR75_18] \]HCVNS3/4Ai.m.\[[@CR42_18]\]E2Micei.m.\[[@CR76_18]\]NS3 to NS5BMice and rhesus macaques\[[@CR31_18]\](SARS)-CoVN1, N2 and N3Micei.m.\[[@CR77_18]\]Spike  +  IL-2Micei.m.\[[@CR78_18], [@CR79_18]\]SpikeMiceHDVL-HDAg; Hbs AgMicei.m.\[[@CR80_18]\]Coxsackievirus 3VP1 or VP3; VP1-1 or VP1-2Mice\[[@CR81_18]\]Japanese encephalitis virusEnvi.m.\[[@CR82_18]\]Herpes viruspgDPigs\[[@CR27_18]\]Foot-and-mouth disease virus (FMDV)cVP1, sVP1, mVP1 or P1Micei.m.\[[@CR83_18]\]VP1Mice\[[@CR84_18]\]Chikungunya virusCapsid E1 and E2Micei.m.\[[@CR85_18]\]AnthraxAnthrax toxin protective AgMice, rats, rabbitsi.m.\[[@CR86_18]\]SmallpoxMiceSkin\[[@CR87_18]\]*Mycobacterium tuberculosis*Ag85AMicei.m.\[[@CR37_18], [@CR88_18]\]Ag85A and ESAT-6  +  proteinsMice and rhesus macaquesi.m.\[[@CR89_18]\]Ag85BMicei.m.\[[@CR90_18]\]*Pseudomonas aeruginosa*OprF/OprIMicei.m.\[[@CR91_18]\]MalariaPfs25i.m.\[[@CR92_18]\]PyCSP and PyHEP17Micei.m., skin\[[@CR93_18]\]*Haemonchus contortus*NPASheepi.m.\[[@CR94_18], [@CR95_18]\]

Capone et al. \[[@CR31_18]\] have demonstrated that gene electrotransfer efficiently increased the cellular immune response both in mice and rhesus macaques vaccinated with a plasmid encoding a nonstructural region of hepatitis C virus (HCV). In particular, they showed by ex vivo interferon (IFN)-γ ELISPOT assay that electroporation in mice induced a fivefold more potent T cell response than DNA administration alone, and that the elicited response was directed against all six of the antigen pools spanning the HCV NS3-NS5B region. To assess whether electroporation treatment elicited similar responses in a nonhuman primate model, they immunized rhesus macaques three times with the vaccine and collected peripheral blood mononuclear cells at periodic intervals to test the T cell effector function. The immune responses observed in the electroporation-treated group showed a faster kinetic, with all the animals responding after the second challenge and reaching a peak after the third. Moreover, all animals treated with electroporation showed both CD4^+^ and CD8^+^ T cell responses, in comparison to the naked DNA group which showed a weaker CD8^+^ response and no CD4^+^ response. Finally, gene electrotransfer-immunized macaques maintained anti-HCV effector T cells for the entire observation period of 6 months, indicating that the gene electrotransfer efficiently elicited a strong memory T cell response.

DNA vaccination in association with electroporation represents an effective strategy to elicit strong, broad, and long-lasting B and T cell responses. Although muscle is the most common target for DNA vaccine immunizations \[[@CR32_18]\], the presence of APCs in both the skin layers makes it an attractive target for nucleic acid vaccination, since direct transfection of APCs may be important for T cell priming upon skin DNA immunization \[[@CR33_18]\] (Fig. [18.2](#Fig2_18){ref-type="fig"}). In a murine model using a viral challenge, Raz et al. \[[@CR34_18]\] have demonstrated that a single intradermal (i.d.) injection (without electroporation) of naked DNA encoding the influenza nucleoprotein gene is sufficient to induce production of antigen-specific antibodies and cytotoxic T lymphocytes that persist for at least 68 weeks and are protective against a lethal challenge with a heterologous strain of influenza virus. Furthermore, immune responses to i.d. DNA vaccination have been recorded to be significantly enhanced by in vivo electroporation \[[@CR35_18]\]; analysis of the antibody response to an Hbs Ag-encoding plasmid delivered i.d. upon electroporation in mice has revealed a strong enhancement of the T~h~1 response, which is mainly characterized by a strong cell-mediated response, compared to that elicited by protein immunization, which showed an exclusively T~h~2 pattern, characterized by a dominant humoral responses. Also, in a nonhuman primate model study carried out in rhesus macaques \[[@CR36_18]\], the i.d.-plus-electroporation group developed 50% more IFN-γ-producing cells and twice more memory T cells than the group not treated with electroporation. Higher antibody responses were recorded in the i.d.-plus-electroporation group when compared to the i.m.-plus-electroporation group. Altogether, these results support the idea that electroporation following DNA injection, both in muscle and skin, represents an effective approach to large animal immunization.Fig. 18.2Cellular targets of EP-mediated DNA vaccination. Current EP approaches following i.d. and i.m. DNA vaccination target skin cells (keratinocytes), muscle cells, and APC (including Langerhans cells) by direct transfection (DT). Application of EP at a local immunization site induces the formation of transient complexes between the DNA and the lipids in the pore edges of the hydrophilic pore zones \[[@CR51_18]\] which facilitate the translocation of plasmid DNA (pDNA) into the cell cytoplasm. Once in the cytosol, pDNA may gain access to the nucleus where transgene expression may occur

Electroporation-Mediated Local Inflammation {#Sec4_18}
-------------------------------------------

Several authors have hypothesized that inflammation caused by electroporation is important to prime the immune response to DNA vaccination \[[@CR19_18], [@CR37_18], [@CR38_18]\]. Local inflammation was previously proposed to ­augment immune responses in studies where pDNA was coinjected with bupivicaine-HCl \[[@CR39_18]--[@CR41_18]\]. The localized tissue damage induced by the electric field is thought to recruit CD3^+^ cells, increasing the number of infiltrating immune cells at the injection site \[[@CR42_18]\]. Indeed, electroporation caused the activation of proinflammatory signals including the expression of chemokines such as MIP-1α, MIP-1β, MIP-1γ, IP-10, MCP-2, and XCL1 \[[@CR18_18]\]. Liu et al. \[[@CR20_18]\] characterized the extent and nature of the cellular infiltrates at the site of electroporative vaccine delivery in mice and found both polymorphonuclear and mononuclear cells localized in the perivascular spaces and throughout the muscle tissue. In particular, they observed a significant increase in B cells, CD4^+^ and CD8^+^ T cells, and a dramatic increase in macrophages and dendritic cells compared to vaccination alone. No difference, however, was recorded among cell populations of blood, spleen, and draining lymph nodes of the mice treated with or without electroporation, suggesting that only local factors are involved in the augmentation of immune responses following electroporation. Also, these authors observed that cell infiltrates were transient and resolved within 2 weeks. Thus, improved antigen presentation may represent one of the mechanisms by which electroporation may elicit a more potent immune response.

Typically, innate immune recognition of the adjuvant component of vaccine formulations has been shown to be critical for their immunogenicity \[[@CR43_18]\]. Many adjuvants are ligands for Toll-like receptors (TLRs), like monophosphoryl lipid A and CpG DNA \[[@CR44_18], [@CR45_18]\], while some conventional adjuvants, such as aluminum hydroxide and incomplete Freud's adjuvant are free of TLR ligands \[[@CR46_18]\]. Therefore, these examples demonstrate that multiple innate immune recognition and signaling pathways are required for adjuvants to function \[[@CR44_18]\]. In the case of DNA vaccines, it has been controversial as to the main vaccine component contributing most to the induction of both innate and adaptive immune responses; while CpG motifs expressed within the plasmid backbone can stimulate innate immunity through TLR 9, the induction of adaptive immune responses were unaffected in the absence of this innate receptor \[[@CR47_18], [@CR48_18]\]. However, it has recently been shown that the double-stranded structure of DNA, independently of CpG sequences, possesses immunomodulatory effects when administered intracellularly \[[@CR44_18]\], which can trigger TLR-independent, TANK-binding kinase I (TBK1)- and INF regulatory factor 3-dependent innate activation of both immune and nonimmune cells to produce type I INFs and their inducible genes \[[@CR49_18], [@CR50_18]\]. Recently, Ishii et al. \[[@CR51_18]\] have reported that the enhancement of DNA vaccine immunogenicity achieved by electroporation may be due to increased transfection rates resulting from this technique, which better contributes to local inflammation by activating cells to produce IFN through the TBK1-dependent signaling pathway. These data suggest that TBK1 is a key signaling molecule for DNA vaccination immunogenicity by regulating innate immune signaling, which is critical for the induction of adaptive immune responses, and that the enhanced immunogenicity of pDNA by electroporation may be a result of more pDNA interacting with intracellular TBK1.

In accordance with this hypothesis, Peng et al. \[[@CR18_18]\] postulated that local inflammation is more important than the actual quantity of expressed transgene in determining the magnitude of the immune response, demonstrated by higher antibody titers and CD4^+^ T cell proliferation rates observed by applying electric pulses 3--7 days prior to i.m. DNA immunization. In this case, it can be postulated that both increased cross-presentation and direct transfection of infiltrating APCs resulting from increased local inflammation may contribute to the augmented immune response in electroporation-mediated DNA vaccination. It appears that the mechanisms by which electroporation enhance the responses to naked plasmid vaccination is by an increase in DNA transfection and possibly include local inflammation, which may be augmented by the magnitude or duration of transgene expression. Indeed, Babiuk et al. \[[@CR19_18]\] observed that the highest level of lymphocytic infiltration was only in muscle tissue treated with electroporation, which elicited higher levels of transgene expression, as was expected considering that antigen production is critical for the retention of the cellular infiltrates at sites of local inflammation.

Electroporation-Mediated DNA Vaccination in Humans {#Sec5_18}
--------------------------------------------------

Although two DNA vaccines have been recently approved in the USA and Canada for the vaccination of horses against West Nile virus \[[@CR52_18]\] and salmon against infectious hematopoietic necrosis virus \[[@CR53_18]\], no DNA vaccine has been approved for use in humans. However, encouraging results from preclinical trials using electroporation technology with DNA vaccination in large animal models has prompted much interest in the technique and its safety. Currently, tolerability in humans has been demonstrated in healthy volunteers \[[@CR54_18]\], anti-DNA antibodies have not been detected in patients electroporated after muscle DNA injection, and the integration of pDNA into host chromosomes following electroporation-mediated delivery has not been observed \[[@CR55_18]\]. Together, these results have been sufficient for the regulatory approval of several clinical trials \[[@CR56_18]\]. As reported on clinicaltrials.gov, seven electrotransfer DNA vaccine trials for cancer and three clinical trials using DNA vaccine against infectious agents in association with electroporation are currently open. Ongoing clinical studies using electroporation-mediated DNA vaccination against infectious agents include three phase I studies involving muscle electroporation. The first will test safety and immunological effects of PENNVAX^™^-B, an HIV vaccine encoding Gag, Pol, and Env, in HIV-infected individuals (VGX Pharmaceuticals, Inc.); the second will assess safety, tolerability, and immunogenicity of human papillomavirus (HPV) DNA Plasmid (VGX-3100^™^) delivered by electroporation in adult females postsurgical or ablative treatment of Grade 2 or 3 Cervical Intraepithelial Neoplasia (VGX Pharmaceuticals, Inc.); the third one, a Phase I/II trial is testing tolerability and efficacy of i.m.-administered CHRONVAC-C^™^ in combination with electroporation in chronic HCV genotype 1 infected and naïve patients with low viral load (Tripep AB).

The amount of pain and distress associated with electroporation in humans has been of a tolerable level for the anticipated benefit \[[@CR57_18]\]. To date, electroporation-mediated DNA vaccination in humans is performed administrating an injection volume of 0.2--0.5 mL followed by short (10--60 ms), low electric field strength (60--250 V/cm) pulses (2--10 pulses). Given that these conditions are efficient for the DNA vaccination of large animals, such as nonhuman primates, they should be sufficient in humans. Electroporation results in a sharp, but quick pain that is comparable to receiving a short electrical shock. While this sensation is transient, administration of short-acting sedative drugs or painkillers before treatment has been considered. Accordingly, as reported by Daud et al. \[[@CR57_18]\], in a clinical trial using an interleukin-12-encoding plasmid delivered by electroporation in patients with metastatic melanoma, in order to limit patients' discomfort, lidocaine was either administered topically or injected around each tumor site, and intravenous analgesic and/or anxiolytic drugs were offered to the patients before electroporation. Notably, previous studies have shown that pain is not a limiting factor as patient discomfort is limited to the period of electrical stimulation, and subjects have usually returned for repeated treatments without asking for sedation. Also, after muscle electroporation, like muscle injection, a mild ache may be experienced at the site of electroporation for some days, and similar to that following a strenuous workout. Several factors determine the strength of pain associated with electroporation, although there is a high interindividual variability in the perception of pain. Among these factors are the number, length, spacing, and thickness of the electrode needles, but primarily the electric pulse parameters dictate the pain threshold \[[@CR58_18]\].

Exclusion criteria for electroporation treatment may include the presence of metal implants near the site of electrical delivery, the presence of a pacemaker, and in the case of muscle electroporation, obesity, since ­treatment efficacy may be decreased if muscle tissue is not reached for vaccine and/or electric pulse delivery.

Electrical Parameters and Electroporation Equipment {#Sec6_18}
===================================================

Electroporation-mediated DNA vaccine delivery requires a pulse generator that controls the parameters of individual pulses or pulse trains (amplitude, duration, number, polarity, wave form, frequency), and electrodes usually integrated into an applicator. Electrodes are in direct contact with the subject to be treated and it is their geometry (shape, size, and distance from each other) that ultimately determines the shape and strength of the electric field and the electrical currents in the target tissue (Fig. [18.3](#Fig3_18){ref-type="fig"}). Thus, both the properties of the pulse(s) and the electrodes are responsible for the desired enhancement of DNA delivery as well as undesirable side effects. Proper design of pulses and electrodes will maximize the effectiveness of a given DNA vaccine and minimize unwanted side effects, such as long-lasting histological changes, pain, and muscle contractions. Further discussion of electroporation parameters and equipment can be found in 10.1007/978-1-4419-8363-3_4 and 10.1007/978-1-4419-8363-3_5.Fig. 18.3Main types of electrodes used for EP. Examples of the two main types of electrodes used for delivering EP: Surface (**a**) and needle-type (**b**) electrodes. Surface electrodes come in the form of caliper electrodes or consist of an array of interweaving electrode fingers (meander). Needle-type electrodes consist of a variable number of (primarily) stainless steel needles arranged in different configurations. Picture depicts a 5-needle array firing rotating chord patterns, a 4-needle array fired in opposing pairs, crossing or triangular patterns, and a 2-needle array firing pin to pin

Skin Electroporation and Equipment {#Sec7_18}
----------------------------------

Skin is a potentially interesting target tissue for DNA vaccines because of its natural role in the immune defense of the body and its ready accessibility. Discussion of gene electrotransfer of DNA in general and to skin can be found in 10.1007/978-1-4419-8363-3_13 and 10.1007/978-1-4419-8363-3_17, respectively.

Conclusion {#Sec8_18}
==========

The goal of any vaccination strategy is to prime a broad and long-lasting immune response that is capable of robust effector responses upon antigenic restimulation \[[@CR59_18]--[@CR61_18]\] and protect against infectious agents, while minimizing toxicity of the vaccine. Since complications may arise due to the use of viral-based ­vectors, such as preexisting immunity regulating vaccine effectiveness and the possibility of reversion into virulence that may decrease vaccine efficacy or safety, alternative approaches should be explored for future vaccine approaches. DNA vaccination appears an even more attractive candidate for future vaccines since it is safe, immunogenic, and does not stimulate vector-specific immunity. Extensive literature supports the hypothesis that electroporation represents a valid approach to vaccine administration in that it increases the consistency and potency of vaccination, inducing higher levels of both antibody-mediated and cytotoxic T cell responses. In this way, electroporation may help augment translocation of exogenous DNA into the nucleus. Furthermore, it has been proven to be effective in enhancing immune responses to antigens regardless of the degree of transgene expression achieved. Recent evidence suggests that innate immune recognition of the adjuvant component of vaccines and the danger signals provided by the method of vaccination may be important in determining the magnitude of the resultant immune response. Electroporation may enhance local inflammation at the site of immunization by facilitating the transfection of greater amounts of pDNA, which may be more readily available to interact with intracellular signaling proteins that trigger the secretion of inflammatory cytokines and their inducible genes. While electroporation-mediated DNA vaccination is currently the topic of intensive research, more theoretical studies and practical trials are required to optimize the delivery of the vaccine into the target tissue, and the electrical parameters facilitating DNA uptake while calibrating local tissue damage and reducing pain associated with vaccine delivery through electroporation.
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